industry // reading the sectorLOADING
This industry spans the companies that discover drugs, insure patients, and supply the tools and devices in between. Value hinges on patents, clinical trial outcomes, and drug-pricing dynamics, so a single approval or patent cliff can reshape a company’s revenue.
| # | Company | Price | Day | Market cap | P/E | Health | |
|---|---|---|---|---|---|---|---|
| 1 | LLY Eli Lilly Eli Lilly makes tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight loss, the drugs behind its recent revenue surge. | $1188.58 | -2.33% | $1.12T | 51.8× | 5/7 | Open → |
| 2 | JNJ Johnson & Johnson Johnson & Johnson develops prescription drugs, including the cancer therapy Darzalex and immunology drugs Stelara and Tremfya, and sells surgical tools, orthopedic implants, and vision products through its MedTech arm. | $256.98 | -0.82% | $618.6B | 23.3× | 3/8 | Open → |
| 3 | ABBV AbbVie AbbVie's immunology drugs Skyrizi and Rinvoq have replaced the revenue Humira lost when biosimilar copies arrived in 2023. | $248.08 | -0.73% | $438.3B | 122.2× | 6/7 | Open → |
| 4 | UNH UnitedHealth UnitedHealth pairs the biggest US health insurer, UnitedHealthcare, with Optum, which runs the OptumRx pharmacy benefit manager, employs or affiliates tens of thousands of physicians, and sells health data analytics to the industry. | $424.62 | -1.64% | $385.6B | 32.1× | 6/8 | Open → |
| 5 | MRK Merck Merck depends heavily on Keytruda, a cancer immunotherapy that accounts for over 40% of sales and loses key US patent protection in 2028. | $123.54 | -1.22% | $305.1B | 17× | 3/7 | Open → |
| 6 | TMO Thermo Fisher Thermo Fisher sells lab instruments, reagents, and single-use consumables that pharma and biotech researchers reorder constantly. | $527.05 | +0.45% | $195.9B | 29.7× | 5/7 | Open → |
| 7 | ABT Abbott Abbott Laboratories spans four segments: medical devices, diagnostics, nutrition, and established pharmaceuticals sold outside the US. | $93.93 | -0.50% | $163.6B | 25.3× | 4/7 | Open → |
| 8 | PFE Pfizer Pfizer sells the blood thinner Eliquis, Prevnar pneumococcal vaccines, and a cancer lineup expanded by its $43 billion Seagen acquisition. | $24.17 | -0.33% | $137.8B | 17.8× | 4/7 | Open → |
Company groupings are curated; figures are real — market caps and prices from EOD market data, health from SEC XBRL filings, and the smart-money activity from Form 4 and STOCK Act disclosures. Educational only, not financial advice.